Document is current
Any future updates will be listed below
-
Authors
Curtis, Jeffrey R. https://orcid.org/0000-0002-8907-8976
Kruzikas, Denise T.
Romero, Ana
Setty, Arathi R.
Peng, Yi
Patel, Jayesh
Reid, Pankti https://orcid.org/0000-0002-7645-0919
Buttgereit, Frank https://orcid.org/0000-0003-2534-550X
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 5 June 2025
First Online: 4 July 2025
Declarations
:
: Jeffrey R. Curtis reported financial relationships with AbbVie Pharmaceuticals, Amgen Inc., Bendcare, Bristol Myer Squib Company, Eli Lilly & Company, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Sanofi, Scipher Medicine Corp., and UCB. Frank Buttgereit reports receiving consultancy fees, honoraria and travel expenses from AbbVie, Horizon Therapeutics, Pfizer, and Sparrow, and grant support from Horizon Therapeutics, Pfizer, and AbbVie. Pankti Reid has reported financial relationships with Amgen, AbbVie and PADCEV. She has also received grant funding from the University of Chicago Institute of Translational Medicine Clinical and Translational Science Award K12/KL2 Grant 5KL2TR002387-05 and has a patent pending regarding the use of interleukin-6 axis inhibitors for viral infection associated pneumonitis. Denise T. Kruzikas, Ana Romero, Arathi R. Setty, Yi Peng, and Jayesh Patel are full-time employees of AbbVie and may own stock options.
: This analysis used de-identified administrative claims database and thus did not require institutional review board approval nor patient consent.
